Insider buying last 90 days
No open-market insider purchases were filed for ZBIO in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every ZBIO insider filing, plotted on the chart in Gekko.Open ZBIO in Gekko
NASDAQ: ZBIO
Zenas BioPharma (ZBIO) Stock Analysis & Forecast
Oct 12 close
$26.40−0.86 (−3.2%)
Gekko Brief
AI summaryOct 12 closeZenas BioPharma's week centers on a wave of clinical and pipeline updates rather than a single catalyst. The company presented new Phase 3 INDIGO open-label extension data for obexelimab in IgG4-related disease at an international symposium, pointing to flare-free probability and reduced glucocorticoid toxicity. Separately, Zenas detailed plans to present seven posters at the ACTRIMS-ECTRIMS meeting in Toronto (21-23 October) covering orelabrutinib and obexelimab in multiple sclerosis, and announced a virtual R&D event for 27 October addressing obexelimab in lupus and the ZB021 program.
Shares closed at $26.40, down 3.2% on the day, sitting between the 50-day average of $30.68 and the 200-day average of $24.94. The stock's one-month return is -15.2%, though the six-month return stands at 25.5%. The GekkoIndex reads 65.3, placing ZBIO in the Accumulation zone, down slightly from five days prior. Fair value is estimated at $37.33, leaving the current price about 29.3% below that mark.
Over the next 20 trading days, the next earnings report is scheduled for 12 November, 30 days out and beyond this window, following an August 12 report where actual EPS of -1.77 missed the -1.12 estimate and triggered a -10% reaction. No insider, Congress, or unusual options activity appears in the recent windows. Analyst coverage shows 4 buy and 1 hold ratings among 5 firms, with a consensus target of $47.88. The Toronto conference and the 27 October R&D event remain near-term dates worth noting.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Zenas BioPharma price vs fair value
Close $26.40200-day averageGekko Fair Value $37.33
Zenas BioPharma quick facts
- Market cap
- $1.67B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$9.63
- Revenue, TTM
- $1.00M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- -0.88
- Volume
- 602,492 avg 762,541
- 1-year return
- −4.9%
- Typical daily move
- ±8.2%
- Typical 20-day move
- ±16.9%
- 50-day average
- $30.68
- 200-day average
- $24.94
- Next earnings
- Nov 12
- Shares outstanding
- 65.18M
Zenas BioPharma swing-trade checklist
Zenas BioPharma scores 3 supportive, 1 mixed and 0 headwinds across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $26.40 sits between the 50-day ($30.68) and 200-day ($24.94) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
65.3, Accumulation
Reading 65.3 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
29.3% below
Price is 29.3% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 31 days
Next report Nov 12, 2026, 31 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityno data
No data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Zenas BioPharma stock chart and price history
Zenas BioPharma closed at $26.40 on Oct 12, 2026, −4.9% over the past year, inside a 52-week range of $13.50 to $44.60.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −15.2%
- 3 months
- −8.3%
- 6 months
- +25.5%
- 1 year
- −4.9%
The full ZBIO chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ZBIO in Gekko
Follow Zenas BioPharma through every session
Put ZBIO on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track ZBIO in GekkoFree for 7 days. No credit card required.
About Zenas BioPharma
Zenas BioPharma is a biopharmaceutical company still in the clinical testing phase, working to build immunology-focused medicines rather than selling finished drugs. Its most advanced candidate, obexelimab, is a bifunctional monoclonal antibody being tested across a range of immune conditions, among them IgG4-related disease, multiple sclerosis, lupus, and a form of autoimmune anemia known as warm AIHA.
Alongside obexelimab, the company is advancing several earlier-stage antibody candidates aimed at different immune targets. These include a treatment directed at TNFa, a fusion molecule built around CTLA-4 and immunoglobulin, an antibody targeting the IGF-1 receptor, and another aimed at complement protein C1s. Each program reflects a different angle on modulating immune system activity for disease treatment.
Originally formed in 2019 as Zenas BioPharma (Cayman) Limited, the business took on its current name in August 2023. It operates out of Waltham, Massachusetts, and its stock trades on the NASDAQ under the ticker ZBIO.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- zenasbio.com
Zenas BioPharma GekkoIndex: the smart money zone
Zenas BioPharma’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 65.3, in the Accumulation zone, down 0.6 points over five sessions.
65.3Accumulation
Down 0.6 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 32 | +2.1% | −3.9% | ||
| Accumulation (current zone) | 148 | +1.0% | +8.8% | ||
| Neutral | 311 | +2.1% | +5.6% | ||
| Distribution | 23 | −6.0% | +2.8% | ||
| Selling | 0 | Not available | |||
Average ZBIO share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the ZBIO price, zone by zone.Track ZBIO in Gekko
Is Zenas BioPharma stock overvalued? Gekko Fair Value
Zenas BioPharma trades 29.3% below Gekko Fair Value of $37.33, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Zenas BioPharma shares are worth, recalculated every trading day.
$37.33
Gekko Fair Value, Oct 10, 2026
29.3% Undervalued
At the end of Aug 2026 the price was 21.1% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open ZBIO in Gekko
Zenas BioPharma insider and Congress trading
No open-market insider purchases were filed for Zenas BioPharma, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in ZBIO were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for ZBIO, plotted on the chart in Gekko.Open ZBIO in Gekko
Buybacks
Zenas BioPharma has been buying back its own shares.
- Bought back, quarter ended Mar 31, 2026
- $592K
- As a share of market cap
- 0.04%
From company filings.
Hedge funds and billionaires quarter ended Dec 31
1of the funds Gekko tracks holds ZBIO.
0added1opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Zenas BioPharma earnings: next date and track record
Zenas BioPharma reports on Nov 12, 2026 (31 days away), and beat the EPS estimate in 2 of its last 8 reports.
Next earnings report
Nov 12, 2026
31 days away
- EPS estimate
- −$1.24
- Revenue estimate
- $1.01M
2 of 8reports beat the EPS estimate
±8.9%average move across the report
4 of 7reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 12, 2026 | −$1.77 est −$1.12 | $1.00M est $15.00M | −10.0% |
| May 13, 2026 | −$1.46 est −$1.37 | — est $25.00M | −1.4% |
| Nov 12, 2025 | −$1.22 est −$0.87 | — est $28.75M | +1.3% |
| Aug 12, 2025 | −$1.25 est −$1.02 | — est $3.75M | +12.1% |
| May 15, 2025 | −$0.80 est −$1.11 | $10.00M est $1.25M | +20.6% |
| Apr 1, 2025 | −$1.26 est −$0.92 | $5.00M | +6.7% |
| Nov 12, 2024 | −$5.02 est −$9.33 | — | −10.2% |
| Aug 22, 2024 | −$1.24 est −$1.24 | — | — |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Zenas BioPharma stock forecast and analyst price targets
Analysts’ average 12-month price target for Zenas BioPharma is $47.88, +81.4% from the last close, from 5 firms rating the stock in the last 90 days.
$47.88consensus 12-month target, +81.4% from the last close
Now $26.40Avg $47.88
Low $22High $55
Each firm’s latest rating in the last 90 days: 5 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 30 | H.C. Wainwright | $44 | +66.7% |
| Sep 30 | Wedbush | $45 | +70.5% |
| Sep 30 | Citi | $48 | +81.8% |
| Sep 21 | H.C. Wainwright | $44 | +66.7% |
| Sep 10 | Citi | $41 | +55.3% |
+8.8%average 20-day move after past Accumulation readings
±8.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Zenas BioPharma market cap and key statistics
Zenas BioPharma’s market cap is $1.67B and revenue of $1.00M over the last twelve months.
Valuation
- Market cap
- $1.67B
- EPS, TTM
- −$9.63
- Gekko Fair Value
- $37.33
Trading
- Volume
- 602,492
- Avg volume, 20 days
- 762,541
- 52-week high
- $44.60
- 52-week low
- $13.50
- Shares outstanding
- 65.18M
Financials
- Revenue, TTM
- $1.00M
- Profit margin
- 0%
- Return on equity
- -199%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- -0.88
- Typical daily move
- ±8.2%
- Typical 20-day move
- ±16.9%
Zenas BioPharma stock news this week
Coverage of Zenas BioPharma this week reads positive: 6 positive, 2 neutral and 0 negative headlines.
- Zenas BioPharma shares new obexelimab data for IgG4-RD treatmentStreetInsider, Oct 12
- Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related DiseaseStock Titan, Oct 12
- Zenas BioPharma to present MS research at Toronto conferenceInvesting.com, Oct 8
- Zenas BioPharma to present MS research at Toronto conference By Investing.comInvesting.com Nigeria, Oct 7
- Zenas BioPharma to present MS drug data at MSToronto2026StreetInsider, Oct 7
- Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026GlobeNewswire, Oct 7
Zenas BioPharma peers
Zenas BioPharma’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Zenas BioPharma stock FAQ
What is Zenas BioPharma’s market cap?
Zenas BioPharma’s market cap is $1.67B at the Oct 12, 2026 close of $26.40, with 65.18M shares outstanding.
What is the Zenas BioPharma stock forecast?
The consensus analyst 12-month price target for Zenas BioPharma is $47.88, +81.4% from the last close. Of the 5 firms that rated the stock in the last 90 days, 4 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Zenas BioPharma stock overvalued or undervalued?
On Gekko’s estimate Zenas BioPharma is undervalued: the Oct 12, 2026 close of $26.40 is 29.3% below Gekko Fair Value of $37.33. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Zenas BioPharma report earnings next?
Zenas BioPharma is expected to report on Nov 12, 2026 (31 days away). Analysts expect earnings of −$1.24 per share on revenue of $1.01M. Zenas BioPharma beat the earnings estimate in 2 of its last 8 reports, moving 8.9% on average across the report.
What is Zenas BioPharma’s 52-week high and low?
Zenas BioPharma’s 52-week high is $44.60 and its 52-week low is $13.50; it closed at $26.40 on Oct 12, 2026, −4.9% over the past year.
Is Zenas BioPharma stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 4 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Zenas BioPharma the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.